Type II Diabetes Mellitus

Metabolic Diseases
8
Pipeline Programs
7
Companies
8
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
1
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
150%
Small Molecule
150%
+ 5 programs with unclassified modality

On Market (2)

Approved therapies currently available

Takeda
ACTOSApproved
pioglitazone
Takeda
oral1999
U
PIOGLITAZONE HYDROCHLORIDEApproved
pioglitazone
Unknown Company
oral2013

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
PioglitazonePhase 41 trial
Active Trials
NCT01972724Completed114Est. Oct 2016
Novartis
NovartisBASEL, Switzerland
1 program
1
VildagliptinPhase 3Small Molecule1 trial
Active Trials
NCT01262586Completed24Est. Mar 2011
Akros Pharma
Akros PharmaNJ - Princeton
2 programs
2
JTT-130Phase 21 trial
JTT-654Phase 21 trial
Active Trials
NCT00929539Completed496Est. Jul 2010
NCT00997152Terminated152Est. Apr 2010
Sanofi
SanofiPARIS, France
1 program
1
LIXISENATIDE AVE0010Phase 2Peptide1 trial
Active Trials
NCT02274740Terminated2Est. Aug 2015
HM
Hua MedicineChina - Shanghai
1 program
1
HMS5552Phase 11 trial
Active Trials
NCT01952535Completed60Est. Dec 2013
Roche
RocheSTAVANGER NORWAY, Norway
1 program
Accu-Chek Smart Pix SoftwareN/A2 trials
Active Trials
NCT02268929Completed414Est. Feb 2017
NCT02156349Completed558Est. Apr 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaPioglitazone
NovartisVildagliptin
SanofiLIXISENATIDE AVE0010
Akros PharmaJTT-654
Akros PharmaJTT-130
Hua MedicineHMS5552
RocheAccu-Chek Smart Pix Software
RocheAccu-Chek Smart Pix Software

Clinical Trials (8)

Total enrollment: 1,820 patients across 8 trials

NCT01972724TakedaPioglitazone

Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy

Start: Dec 2013Est. completion: Oct 2016114 patients
Phase 4Completed
NCT01262586NovartisVildagliptin

Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.

Start: Nov 2010Est. completion: Mar 201124 patients
Phase 3Completed
NCT02274740SanofiLIXISENATIDE AVE0010

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

Start: Apr 2015Est. completion: Aug 20152 patients
Phase 2Terminated
NCT00997152Akros PharmaJTT-654

Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

Start: Sep 2009Est. completion: Apr 2010152 patients
Phase 2Terminated
NCT00929539Akros PharmaJTT-130

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Start: Jun 2009Est. completion: Jul 2010496 patients
Phase 2Completed
NCT01952535Hua MedicineHMS5552

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers

Start: Sep 2013Est. completion: Dec 201360 patients
Phase 1Completed
NCT02268929RocheAccu-Chek Smart Pix Software

A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.

Start: Oct 2014Est. completion: Feb 2017414 patients
N/ACompleted
NCT02156349RocheAccu-Chek Smart Pix Software

A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.

Start: May 2014Est. completion: Apr 2017558 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
20h ago

(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)

Johnson & Johnson
Beerse, Antwerp, Belgium
Yesterday

Computational Chemist

Topos Bio
San Francisco Office
2d ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr

Senior Specialist, Quality Management Systems

Crinetics Pharmaceuticals
San Diego, CA
4d ago
$91K - $114K/yr

Director, Quality Systems, Project Management, QRM, RS

Crinetics Pharmaceuticals
US California
4d ago
$178K - $223K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)